These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36709108)

  • 1. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
    Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
    Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
    Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Wei H; Zhou C; Liu B; Lin D; Li Y; Wei S; Gong B; Zhang G; Liu K; Gong X; Fang Q; Liu Y; Qiu S; Gu R; Song Z; Chen J; Yang M; Zhang J; Jin J; Wang Y; Mi Y; Wang J
    Br J Haematol; 2022 May; 197(4):442-451. PubMed ID: 35274287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
    Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
    Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
    Wang B; Wen L; Wang Z; Chen S; Qiu H
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
    Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Deng DX; Zhu HH; Liu YR; Chang YJ; Ruan GR; Jia JS; Jiang H; Jiang Q; Zhao XS; Huang XJ
    Leuk Lymphoma; 2019 Sep; 60(9):2181-2189. PubMed ID: 30773106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia.
    Ding Y; Liu Z; Wang H; Xiong S; Zhai Z
    Scand J Clin Lab Invest; 2023 Sep; 83(5):340-347. PubMed ID: 37355341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
    Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
    J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
    Tarlock K; Lamble AJ; Wang YC; Gerbing RB; Ries RE; Loken MR; Brodersen LE; Pardo L; Leonti A; Smith JL; Hylkema TA; Woods WG; Cooper TM; Kolb EA; Gamis AS; Aplenc R; Alonzo TA; Meshinchi S
    Blood; 2021 Sep; 138(13):1137-1147. PubMed ID: 33951732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
    Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
    Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
    Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and clinical impact of WT1 mutations in the context of CEBPA-mutated acute myeloid leukemia.
    Wang T; Hua H; Wang Z; Wang B; Cao L; Qin W; Wu P; Cai X; Chao H; Lu X
    Hematology; 2022 Dec; 27(1):994-1002. PubMed ID: 36066283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Impact of
    Li RQ; Wen XL; Zhang XL; Dong CX; Wang MF; Liu XX; Huang YJ; Tan YH; Chang JM; Zhang RJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):628-632. PubMed ID: 37356918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of Flow Cytometric MRD Detection at Different Time Points during AML Chemotherapy on Prognosis].
    Ju RX; Sun FQ; Wang YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1051-1057. PubMed ID: 39192397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
    J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
    Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.